ENDO pushing BNC
ENDO is doing very well these days and many biotech analysts cover Endo.
They know about BNC.
BNC is becoming a beta play on ENDO attracting new interest and buying.
What convince me to enter BNC as one of my top picks is the fact that ENDO is the world leader in bladder cancer.
They are the experts.
IF someone can make an opinion on the drug they are that someone.
To 2$ we go on just buzz, much higher on news day.
0.25 of cash.
The stock is trading with 1$ or so of speculative value.
Not much. Very cheap still.